Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Osteoporosis treatment].

B Uebelhart1, R Rizzoli

  • 1Service des maladies osseuses, Centre collaborateur de I'OMS pour la prevention de l'ostéoporose, Departement de rehabilitation et gériatrie, HUG, 1211 Geneve 14. Brigitte.Uebelhart@hcuge.ch

Revue Medicale Suisse
|February 10, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Non-metastatic breast cancer patients discontinuing aromatase inhibitor on denosumab: what next?

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same author

Re: Bobelyak M, Vaculik J, Stepan JJ. Bone mineral density assessment using Radiofrequency Echographic Mult Spectrometry (REMS) in patients before and after total hip replacement, Osteoporos Int 2025;https://doi.org/10.1007/s00198-025-07685-w and Re: Pocock N, Chan D. Editorial: Is REMS-BMD truly a measured parameter? A call for transparency and technical clarification, Osteoporos Int 2025;https://doi.org/10.1007/s00198-025-07699-4.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2025
Same author

Optimisation of vitamin D status in global populations.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2024
Same author

Comparing Prevalence of Sarcopenia Using Twelve Sarcopenia Definitions in a Large Multinational European Population of Community-Dwelling Older Adults.

The journal of nutrition, health & aging·2023
Same author

Effects of Vitamin D, Omega-3 Fatty Acids and a Home Exercise Program on Prevention of Pre-Frailty in Older Adults: The DO-HEALTH Randomized Clinical Trial.

The Journal of frailty & aging·2023
Same author

Prevalence of Physical Frailty: Results from the DO-HEALTH Study.

The Journal of frailty & aging·2022
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
See all related articles

Adherence to osteoporosis treatments is low. Certain medications like strontium ranelate and bisphosphonates can prevent fractures and improve bone density, but may carry risks like osteonecrosis.

Area of Science:

  • Bone health and osteoporosis management.
  • Pharmacological interventions for skeletal diseases.
  • Nutritional impacts on fracture risk.

Context:

  • Osteoporosis treatment adherence is a significant challenge in chronic disease management.
  • Hip fractures pose a serious risk, particularly in elderly populations.
  • Various pharmaceutical agents are used to manage osteoporosis and related conditions.

Purpose:

  • To review current treatments for osteoporosis and their efficacy.
  • To highlight the role of specific medications in fracture prevention and bone density improvement.
  • To discuss potential adverse effects associated with osteoporosis therapies.

Summary:

  • Folates and vitamin B12 may reduce hip fracture risk in stroke patients.

Related Experiment Videos

  • Raloxifene shows promise in reducing estrogen receptor-positive breast cancer and cardiovascular events.
  • Strontium ranelate effectively prevents hip fractures in elderly women.
  • Alendronate demonstrates a greater impact on bone mineral density and remodeling markers than risedronate.
  • Monthly ibandronate enhances bone mineral density in postmenopausal women.
  • Bisphosphonates carry a risk of excessive bone remodeling suppression and osteonecrosis.

    • Impact:

    • Provides an overview of osteoporosis treatment options and their comparative effects.
    • Informs clinicians and patients about the benefits and risks of different osteoporosis medications.
    • Highlights the need for careful monitoring of patients undergoing bisphosphonate therapy.